Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Zhang, Yuan; Almazi, Juhura G.; Ong, Hui Xin; Johansen, Matt D.; Ledger, Scott; Traini, Daniela; Hansbro, Philip M.; Kelleher, Anthony D.; Ahlenstiel, Chantelle

doi:10.3390/ijms23052408

Cited by 23 publications

(12 citation statements)

References 305 publications

(317 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other researchers also selected the same genes (1a and 1ab) as the best targets for siRNAs [ 28 ], although additional SARS-CoV-2 genes were also silenced by siRNA, achieving good results both in cell lines and in animal models [ 25 ]. Recently, siRNA treatment against SARS-CoV-2 was authorized for a clinical trial in Europe [ 29 ] because it achieved promising results in preclinical models [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Casseb

Khayat²,

Souza³

et al. 2022

Genes

View full text Add to dashboard Cite

The COVID-19 pandemic initiated a race to determine the best measures to control the disease and to save as many people as possible. Efforts to implement social distancing, the use of masks, and massive vaccination programs turned out to be essential in reducing the devastating effects of the pandemic. Nevertheless, the high mutation rates of SARS-CoV-2 challenge the vaccination strategy and maintain the threat of new outbreaks due to the risk of infection surges and even lethal variations able to resist the effects of vaccines and upset the balance. Most of the new therapies tested against SARS-CoV-2 came from already available formulations developed to treat other diseases, so they were not specifically developed for SARS-CoV-2. In parallel, the knowledge produced regarding the molecular mechanisms involved in this disease was vast due to massive efforts worldwide. Taking advantage of such a vast molecular understanding of virus genomes and disease mechanisms, a targeted molecular therapy based on siRNA specifically developed to reach exclusive SARS-CoV-2 genomic sequences was tested in a non-transformed human cell model. Since coronavirus can escape from siRNA by producing siRNA inhibitors, a complex strategy to simultaneously strike both the viral infectious mechanism and the capability of evading siRNA therapy was developed. The combined administration of the chosen produced siRNA proved to be highly effective in successfully reducing viral load and keeping virus replication under control, even after many days of treatment, unlike the combinations of siRNAs lacking this anti-anti-siRNA capability. Additionally, the developed therapy did not harm the normal cells, which was demonstrated because, instead of testing the siRNA in nonhuman cells or in transformed human cells, a non-transformed human thyroid cell was specifically chosen for the experiment. The proposed siRNA combination could reduce the viral load and allow the cellular recovery, presenting a potential innovation for consideration as an additional strategy to counter or cope COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Casseb

Khayat²,

Souza³

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…However, several nanomaterials and technology are candidate to help in the prevention, diagnosis and treatment of SARS-CoV-2 infection and COVID-19 disease. This is the case of some RNA interference (RNAi) formulations to knock-down key viral genes to limit or inhibit viral infection and progression (Idris et al, 2021;Zhang et al, 2022b;Saify Nabiabad et al, 2022). Several in vitro studies using these RNAi preparations have obtained promising results against SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19

Valenzuela-Fernandez

Cabrera-Rodríguez

Ciuffreda

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the associated coronavirus disease 2019 (COVID-19), which severely affect the respiratory system and several organs and tissues, and may lead to death, have shown how science can respond when challenged by a global emergency, offering as a response a myriad of rapid technological developments. Development of vaccines at lightning speed is one of them. SARS-CoV-2 outbreaks have stressed healthcare systems, questioning patients care by using standard non-adapted therapies and diagnostic tools. In this scenario, nanotechnology has offered new tools, techniques and opportunities for prevention, for rapid, accurate and sensitive diagnosis and treatment of COVID-19. In this review, we focus on the nanotechnological applications and nano-based materials (i.e., personal protective equipment) to combat SARS-CoV-2 transmission, infection, organ damage and for the development of new tools for virosurveillance, diagnose and immune protection by mRNA and other nano-based vaccines. All the nano-based developed tools have allowed a historical, unprecedented, real time epidemiological surveillance and diagnosis of SARS-CoV-2 infection, at community and international levels. The nano-based technology has help to predict and detect how this Sarbecovirus is mutating and the severity of the associated COVID-19 disease, thereby assisting the administration and public health services to make decisions and measures for preparedness against the emerging variants of SARS-CoV-2 and severe or lethal COVID-19.

show abstract

“…Other researchers also selected the same genes (1a and 1ab) as the best targets for siRNAs [19], although additional SARS-CoV-2 genes were also silenced by siRNA, achieving good results both in cell lines and in animal models [17]. Recently, siRNA treatment against SARS-CoV-2 was authorized for a clinical trial in Europe [20]because it achieved promising results in preclinical models [21].…”

Section: Discussionmentioning

confidence: 99%

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Casseb¹,

Khayat²,

Souza³

et al. 2022

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic initiated a race to determine the best measures to control the disease and to save as many people as possible. Efforts to implement social distancing, the use of masks, and massive vaccination programs turned out to be essential in reducing the devastating effects of the pandemic. Nevertheless, the high mutation rates of SARS-CoV-2 challenge the vaccination strategy and maintain the threat of new outbreaks due to the risk of infection surges and even lethal variations able to resist the effects of vaccines and upset the balance. Most of the new therapies tested against SARS-CoV-2 came from already available formulations developed to treat other diseases, so they were not specifically developed for SARS-CoV-2. In parallel, the knowledge produced regarding the molecular mechanisms involved in this disease was vast due to massive efforts worldwide. Taking advantage of such a vast molecular understanding of virus genomes and disease mechanisms, a targeted molecular therapy based on siRNA specifically developed to reach exclusive SARS-CoV-2 genomic sequences was tested in a non-transformed human cell model. Since coronavirus can escape from siRNA by producing siRNA inhibitors, a complex strategy to simultaneously strike both the viral infectious mechanism and the capability of evading siRNA therapy was developed. The combined administration of the chosen produced siRNA proved to be highly effective in successfully reducing viral load and keeping virus replication under control, even after many days of treatment, unlike the combinations of siRNAs lacking this anti-anti-siRNA capability. Additionally, the developed therapy did not harm the normal cells, which was demonstrated because, instead of testing the siRNA in nonhuman cells or in transformed human cells, a non-transformed human thyroid cell was specifically chosen for the experiment. The proposed siRNA combination deeply reduced the viral load throughout the experiment and allowed cellular recovery, thus representing a potential innovation, to be considered as an additional weapon for therapy of COVID-19 and even other infectious diseases.

show abstract

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Cited by 23 publications

References 305 publications

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms

Contact Info

Product

Resources

About